Year: 2020

San Juan, PUERTO RICO, Nov. 09, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI) (The “Company”) an emerging innovator of products, technologies, and services for the rapidly growing cyber-security, digital robotics automation, and A.I. for manufacturing industry announced today that its wholly-owned subsidiary, First Bitcoin Capital LLC, is in discussions with a major law firm in order to enforce our  Bitcoin ATM Patent against those operating Bitcoin ATMs, to collect royalty payments.  While in these negotiations, we are reaching out to individual operators to reach an amicable arrangement without litigation while offering those operators to join a consortium of Bitcoin ATMs.As Bitcoin prices surge to their highest levels since 2018, reaching over $15,000.00, we expect transactions in this lucrative market to increase...

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent OfficesComposition-of-matter patents protect THR-687 until 2039-2044Leuven, Belgium and Boston, MA, November 9, 2020 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing potential next generation standard-of-care therapies to better preserve the vision of patients with diabetic macular edema (DME), today announces a further strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME.The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-of-matter patents covering THR-687. Patents EP3613739 and US10703752 were issued in November 2020 and July 2020 respectively, and expire in...

Montrouge, France, November 9, 2020DBV Technologies to Participate in Upcoming Investor ConferencesDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following virtual investor conferences. At each conference, Daniel Tassé, Chief Executive Officer, will participate in a fireside chat.Credit Suisse Healthcare Conference, November 9-12.The fireside chat will take place on Wednesday, November 11, 2020 at 12:30PM ET.Stifel Healthcare Conference, November 16.The fireside chat will take place on Monday, November 16, 2020 at 8AM ET.  Evercore HealthconX, December 1-3.The fireside chat will take place on Tuesday, December 1, 2020 at 12:35PM ET.  A live webcast of the fireside chats will be available on the Investors & Media...

Montrouge, France, le 9 novembre (7h30 CET) 2020DBV Technologies invitée à présenter lors de prochaines conférences InvestisseursDBV Technologies (Euronext: DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui sa participation aux conférences investisseurs virtuelles suivantes. Lors de chaque conférence Daniel Tassé, Directeur Général, participera à un « fireside chat ».Crédit Suisse Healthcare Conference, 9 au 12 novembre.Le “fireside chat” aura lieu le mercredi 11 novembre 2020 à 12h30 ET (18h30 heure française).Stifel Healthcare Conference, 16 novembre.Le “fireside chat” aura lieu lundi 16 novembre 2020 à 8h ET (14h heure française).Evercore HealthconX, 1 au 3 décembre.Le “fireside chat” aura lieu le mardi 1er décembre 2020 à 12h35 ET (18h35 heure française).Une...

November 9, 2020Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that management will participate in several upcoming investor conferences:Guggenheim Healthcare Talks | Idea Forum | 2nd Annual Neuro/Immunology Day on November 16, 2020. Management will participate in 1×1 meetings.Stifel 2020 Virtual Healthcare Conference. Fireside chat on November 17, 2020 at 2:00 p.m. ET.Wolfe Research Virtual Healthcare Conference on November 19, 2020. Management will participate in 1×1 meetings.Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. Fireside chat available to conference participants on-demand.3rd Annual Evercore ISI HealthCONx Conference...

 Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that ObsEva’s Board of Directors has appointed Brian O’Callaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will also be proposed for election on ObsEva’s Board of Directors at next company AGM.As ObsEva evolves from a development company towards commercialization, Dr Ernest Loumaye, co-founder and CEO of ObsEva, has expressed his wish to retire from the day to day operation. He will continue to serve as a member of ObsEva’s Board of Directors and will work to ensure a smooth transition with Brian O’Callaghan. Brian...

­­Orphazyme A/SCompany announcement                                                                                       No. 70/2020                                                                                                         Company Registration No. 32266355Follows U.S. Food and Drug Administration (FDA) acceptance of New Drug Application (NDA) with Priority Review in September 2020Regulatory decisions expected in 2021Copenhagen, Denmark, November 9, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its investigational product candidate arimoclomol for the treatment of Niemann-Pick...

SIKA FURTHER EXPANDING PRODUCTION IN FRANCE AND POSITIONING ITSELF FOR INFRASTRUCTURE INVESTMENTSSika has started production of shotcrete admixtures at its main plant at Gournay–en-Bray, north west of Paris. The set accelerator marketed under the Sigunit® brand is used primarily in tunnel construction. The market potential in France and beyond is considerable – in western Europe alone, tenders have been issued for tunnel construction projects with a combined length of 900 kilometers, with these projects set to come on stream over the next few years.A crucial factor in shotcrete as it is applied in mining and tunneling is high early strength development. Admixtures in the form of a set accelerator ensure that the shotcrete bonds to rock and concrete, thus facilitating overhead spraying.INFRASTRUCTURE INVESTMENTS OF CHF 750 BILLION...

SIKA BAUT IN FRANKREICH PRODUKTION WEITER AUS UND POSITIONIERT SICH FÜR INFRASTRUKTURINVESTITIONENSika hat in ihrem Hauptwerk in Gournay-en-Bray nordwestlich von Paris die Produktion von Additiven für Spritzbeton aufgenommen. Die unter dem Markennamen Sigunit® vertriebenen Erstarrungsbeschleuniger werden vor allem im Tunnelbau eingesetzt. Das Marktpotenzial ist über Frankreich hinaus gross – allein in Westeuropa sind Tunnelbauprojekte mit einer Gesamtlänge von 900 Kilometern ausgeschrieben, die in den nächsten Jahren realisiert werden.Bei Spritzbeton, wie er im Berg- oder Tunnelbau zum Einsatz kommt, ist eine hohe Frühfestigkeitsentwicklung wichtig. Additive in Form von Erstarrungsbeschleunigern sorgen für die Haftung des Spritzbetons auf Fels und Beton und erleichtern somit die Spritzarbeiten über Kopf.INFRASTUKTURINVESTITIONEN VON CHF...

SEB:s Boprisindikator minskar med 3 enheter i november, från 58  till 55, men är fortfarande på en betydligt högre nivå än innan coronapandemin slog till. På regional nivå är skillnaderna större och indikatorn ligger i de sex regionerna mellan 44 och 74. Hushållens förväntningar på reporäntans nivå ökar något och ligger i november på 0,40 procent. Andelen som planerar att binda sina rörliga lån stiger och ligger på 6 procent, vilket är betydligt fler än förra månaden.Andelen hushåll som tror på stigande priser minskar med 1 procentenhet från förra månaden till 64 procent. Andelen hushåll som tror på sjunkande priser det kommande året uppgår nu till 9 procent, att jämföra med 7 procent föregående månad. Andelen som tror på oförändrade priser minskar från 22 till 20 procent. Boprisindikatorn är skillnaden mellan andelen som tror på stigande...